Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 106 to 120 of 666 results for kidney or kidneys or renal

  1. Chronic kidney disease

    All NICE products on chronic kidney disease. Includes any guidance, advice and quality standards.

  2. Ravulizumab for preventing kidney events in people with chronic kidney disease at high risk after a cardiopulmonary bypass [ID6632]

    Awaiting development Reference number: GID-TA11841 Expected publication date: TBC

  3. Laparoscopic cryotherapy for renal cancer (HTG271)

    Evidence-based recommendations on laparoscopic cryotherapy for renal cancer. This involves inserting a surgical instrument (cryoprobe) to apply freezing temperatures to the tumour and destroy the cancer cells.

  4. Diabetes (type 1 and type 2) in children and young people: diagnosis and management (NG18)

    This guideline covers the diagnosis and management of type 1 and type 2 diabetes in children and young people aged under 18. The guideline recommends how to support children and young people and their families and carers to maintain tight control of blood glucose to reduce the long-term risks associated with diabetes.

  5. Percutaneous cryotherapy for renal cancer (HTG269)

    Evidence-based recommendations on percutaneous cryotherapy for renal tumours. This involves inserting instruments that apply cold temperatures into the tumour to destroy the cancer cells.

  6. Can risk of contrast-induced acute kidney injury be stratified by eGFR thresholds?

    Recommendation ID NG148/1 Question Can risk of contrast-induced acute kidney injury be stratified by eGFR thresholds? Any explanatory...

  7. Hyperparathyroidism (primary): diagnosis, assessment and initial management (NG132)

    This guideline covers diagnosing, assessing and managing primary hyperparathyroidism. It aims to improve recognition and treatment of this condition, reducing long-term complications and improving quality of life.

  8. Percutaneous radiofrequency ablation for renal cancer (HTG226)

    Evidence-based recommendations on percutaneous radiofrequency ablation of renal cancer. This involves using heat produced through electrodes placed into the tumour to destroy the cancer cells.

  9. Dapagliflozin for treating chronic heart failure with reduced ejection fraction (TA679)

    Evidence-based recommendations on dapagliflozin (Forxiga) for symptomatic chronic heart failure with reduced ejection fraction in adults.

  10. Past appeals and decisions

    Past technology appraisal appeals and decisions

  11. Hypertension in adults (QS28)

    This quality standard covers managing hypertension in adults. It includes diagnosis and investigations, treatment and specialist referral. It describes high-quality care in priority areas for improvement.

  12. Myeloma: diagnosis and management (NG35)

    This guideline covers the diagnosing and managing of myeloma (including smouldering myeloma and primary plasma cell leukaemia) in people aged 16 and over. It aims to improve care for people with myeloma by promoting the most effective tests and treatments for myeloma and its complications.

  13. Nivolumab with cabozantinib for untreated advanced renal cell carcinoma (terminated appraisal) (TA785)

    NICE is unable to make a recommendation on nivolumab (Opdivo) with cabozantinib for untreated advanced renal cell carcinoma. This is because Bristol Myers Squibb withdrew the evidence submission.

    Sections for TA785

  14. Lenvatinib with everolimus for previously treated advanced renal cell carcinoma (TA498)

    Evidence-based recommendations on lenvatinib (Kisplyx) with everolimus for previously treated advanced renal cell carcinoma in adults.